Global cannabis industry is still in its infancy; and in 2017, the global medical cannabis market size was valued at US$11.4B and expected to grow to ~US$55.8B with CAGR ~19%, as per forecast by many experts. With this, many pot stocks have come under limelight while the future is still a bit hazy. On the other hand, the legislative scenario seems to be turning a bit positive. Given this backdrop, below is a look at some key pot stocks.
AusCann Group Holdings Ltd (ASX: AC8), which develops clinically validated cannabinoid medicines, is offering Share Purchase Plan to raise a maximum of $8 million. They also raised over $33.4 million (before costs) (Placement) from investors in North America. The group intends to use these funds for Clinical studies for product registration in Australia, expand manufacturing plant in Australia for final dose form manufacturing, setup a manufacturing facility in Chile and conduct R&D of cannabinoid pharmaceuticals. The stock has moved up about 134% in last one year but slipped by about 44% in last three months.
The Hydroponics Company Ltd (ASX: THC) is into worldwide cannabis business and lately got Northern NSW cannabis site and is expediting regulatory approval lodging and site development for THC owned strains as well as imported strains from international commercial partners. Their Northern NSW site is a form of primary cannabis source for the group’s manufacturing operation in Queensland. They made an off-take agreement for THC’s medicinal cannabis for use by Meluka Health and finished a supply agreement for Meluka’s tea-tree extract for use in THC medicinal cannabis products. In one year, the stock moved up by 119% but slipped by 16% in last three months. [optin-monster-shortcode id=”swikrbu1d9j9aq0o4cko”]
Zelda Therapeutics Ltd (ASX: ZLD) is focused on developing a range of cannabinoid-based formulations for treating several medical conditions. The group lately appointed Dr. Richard Hopkins as the Managing Director, effective 16 July 2018. Their initial in vitro results show pure cannabidiol (CBD) and pure ?9 – tetrahydrocannabinol (THC) with each having anti-cancer activity in pediatric medulloblastoma cell lines. The next phase will entail checking effectiveness of the formulations under comparative analysis and in-vivo model.
Creso Pharma Ltd (ASX: CPH) is another player that has been expecting revenues from animal and human product launches in Switzerland and selected EU countries in 2018. The group is targeting to position well in the growing market opportunity with several products in pipeline for human and animal nutraceutical markets. They made exclusive licensing deals that give them unique drug delivery IP and substantial distribution globally. In last six months, the stock has fallen about 36%.
Creso Pipeline (Source: Company reports)
Stemcell United Ltd (ASX: SCU) is a bio-technology company which focuses on stem cells for medicinal, health and beauty applications and the group aims to commercialise the use of their proprietary technology for cannabis stem cell extraction in cooperation with Yunnan Hua Fang Industrial Hemp Co Ltd. The group recently won a contract to supply 50 tonnes of Daemonorops Draco Blume extract (Resina) to Chinese customer over a five year period. While the stock has been down about 36% in last six months, but it rose about 8% in last one month.
MMJ Phytotech Ltd (ASX: MMJ) is another global cannabis investment company that announced results of the Phase 2 clinical trial undertaken by its wholly-owned subsidiary PhytoTech Therapeutics (PTL). The group announced about selling PTL to Harvest One Cannabis Inc. (TSX-V:HVT), which has been subject to MMJ shareholder approval. PTL finished Phase 2 clinical trial which is an open-label, single-centre clinical study to evaluate the safety, tolerability and efficacy of oral administration of the Satipharm CBD capsules as an adjunctive treatment to children suffering from refractory, or treatment-resistant epilepsy. The stock was down 7% on July 27, 2018.
Cann Group Ltd (ASX: CAN), is yet another but resilient group focused on breeding, cultivating and manufacturing medicinal cannabis for sale and use within Australia and internationally; and the group lately made an agreement to lease and build their Cann Group’s Stage 3 cultivation and GMP manufacturing facility. The investment of this facility is expected to be over $100 million. Australia Pacific Airports (Melbourne) proposed to fund and conduct primary build of the facility. The Site agreement enables for having a huge facility as well as compared to the earlier expansion options scopes. The Commissioning of the facility is expected 12 months from design completion.
While the pot stocks are yet to report profits, these are on the radar to be watched out at a continuous basis.
The Income available from dividends remains attractive for many investors.
We take a look at the best yields on the market and assess what they say about a company’s prospect.
One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”
ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.
Click here to get your free report.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.